Company

Livzon Pharma Wins Approval for China's First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty
HKG: 1513Livzon Pharmaceutical

Livzon Pharma Wins Approval for China’s First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty

Livzon Pharmaceutical Group Inc. (SHE: 000513; HKG: 1513) announced that the National Medical Products Administration (NMPA) has granted marketing approval for its Leuprorelin Acetate Microspheres for Injection, 11.25 mg (3‑month…

Hybio Pharmaceutical's AI‑Designed Triple Agonist HY3003 Clears FDA IND Filing for Obesity – GLP‑1/GIP/Glucagon Tri‑Target Drug Outperforms Tirzepatide and Retatrutide in Preclinical Weight Loss

Hybio Pharmaceutical’s AI‑Designed Triple Agonist HY3003 Clears FDA IND Filing for Obesity – GLP‑1/GIP/Glucagon Tri‑Target Drug Outperforms Tirzepatide and Retatrutide in Preclinical Weight Loss

Gan & Lee's Insulin Aspart Wins Ethiopian Registration – First Rapid‑Acting Insulin Analogue Approved in Africa's Second‑Most‑Populous Nation

Gan & Lee’s Insulin Aspart Wins Ethiopian Registration – First Rapid‑Acting Insulin Analogue Approved in Africa’s Second‑Most‑Populous Nation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Bao PharmaceuticalsClinical trial approval / initiation

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

CRO / CMO / CDMOCTSMED Pharmaceutical Technology

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

AbbVieClinical trial results

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
Market launchOTCMKTS: RHHBY

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Show More